In the realm of cancer immunotherapy, certain transcription factors have been recognized for their pivotal roles in orchestrating immune responses and influencing the tumor microenvironment. Research on transcription factors such as ENO1, SETD2, nectin-4, TROP2, gasdermin E (GSDME), TCF-7, and glutathione peroxidase 4 (GPX4) has gathered increased attention in the past three years showing increased growth in journal and patent publications based on the CAS Content Collection (Fig. ). As understanding of the complex interplay between transcription factors and the immune system deepens, it can be expected that transcription factorbased biomarkers will play an increasingly important role in the quest for precision cancer immunotherapy.